The latest price target for DarioHealth (NASDAQ:DRIO) was reported by Stifel on April 1, 2024. The analyst firm set a price target for $4.00 expecting DRIO to rise to within 12 months (a possible 359.08% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for DarioHealth (NASDAQ:DRIO) was provided by Stifel, and DarioHealth maintained their buy rating.

The last upgrade for DarioHealth Corp happened on May 13, 2022 when Alliance Global Partners raised their price target to N/A. Alliance Global Partners previously had a neutral for DarioHealth Corp.

There is no last downgrade for DarioHealth.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DarioHealth, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DarioHealth was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.

While ratings are subjective and will change, the latest DarioHealth (DRIO) rating was a maintained with a price target of $0.00 to $4.00. The current price DarioHealth (DRIO) is trading at is $0.87, which is within the analyst’s predicted range.